I’m curious about how many of our participants monitor vorapaxar (Zontivity®, New American Therapeutics, Inc) antiplatelet therapy. Vorapaxar is the only protease-activated receptor-1 (PAR-1) antagonist that reduces thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease, FDA-approved in 2014. Vorapaxar is used alongside dual antiplatelet therapy (aspirin and clopidogrel; aspirin and ticagrelor) and fully suppresses thrombin receptor agonist peptide (TRAP)-induced platelet aggregation after one week of treatment. Upon discontinuation, the antiplatelet effect measured by TRAP aggregometry lasts at least four weeks. Vorapaxar does not affect ADP, collagen, or arachidonic acid-induced aggregation, and does not affect coagulation parameters. Please add your comments here or email to [email protected].